Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome.

@article{Cramer2004EffectsOA,
  title={Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome.},
  author={Clay T. Cramer and Brian Goetz and Krista L M Hopson and Gregory J. Fici and Rose M Ackermann and Stephen C. Brown and Charles L. Bisgaier and Walajapet G. Rajeswaran and Daniela C. Oniciu and Michael E. Pape},
  journal={Journal of lipid research},
  year={2004},
  volume={45 7},
  pages={1289-301}
}
We have identified a novel omega-hydroxy-alkanedicarboxylic acid, ESP 55016, that favorably alters serum lipid variables in obese female Zucker (fa/fa) rats. ESP 55016 reduced serum non-HDL-cholesterol (non-HDL-C), triglyceride, and nonesterified fatty acid levels while increasing serum HDL-C and beta-hydroxybutyrate levels in a dose-dependent manner. ESP 55016 reduced fasting serum insulin and glucose levels while also suppressing weight gain. In primary rat hepatocytes, ESP 55016 increased… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 68 references

Long-Chain-Fatty-Acid CoA Ligases: The Key to Fatty Acid Activation, Formation of Xenobiotic Acyl-CoA Thioesters and Lipophilic Xenobiotic Conjugates

  • K. M. Knights
  • Curr. Med. Chem.-Immun.,Endoc, & Metab. Agents
  • 2003
2 Excerpts

Similar Papers

Loading similar papers…